Hydrazide derivatives

1. Definition and General Overview

• Hydrazide derivatives are a class of organic compounds containing the –CONHNH₂ functional group (hydrazide moiety) or a substituted variant of it.

• Many hydrazide derivatives are synthetic pharmaceuticals with antibacterial, antitubercular, antineoplastic, or other pharmacological actions.

• Structurally derived from hydrazine (NH₂–NH₂) by replacing one hydrogen atom with an acyl group, forming an acyl hydrazide.

• The most well-known therapeutic members include isoniazid and hydralazine.

• Mechanisms of action vary widely across subclasses, often involving enzyme inhibition or interaction with nucleic acids.

---

2. Chemical and Pharmacological Features

• General formula: R–CO–NH–NH₂ (where R is an alkyl, aryl, or heterocyclic group).

• Hydrazide group allows formation of hydrazones with aldehydes and ketones, a property important in their biochemical activity.

• Lipophilicity, substituents, and molecular size influence cell penetration, target binding, and pharmacokinetics.

• Many are prodrugs that require in vivo activation to reactive species.

---

3. Therapeutic Subclasses and Examples

A. Antitubercular Hydrazides

• Isoniazid (isonicotinic acid hydrazide)

  • Mechanism: Inhibits mycolic acid synthesis in Mycobacterium tuberculosis by targeting the InhA enoyl-ACP reductase enzyme.

  • Role: First-line agent in tuberculosis therapy.

  • Key features: Bactericidal against actively dividing TB bacilli; resistance linked to katG mutations.

• Iproniazid (obsolete as TB drug, historical antidepressant).

B. Antihypertensive Hydrazides

• Hydralazine

  • Mechanism: Direct arteriolar vasodilator; reduces peripheral resistance by relaxing vascular smooth muscle.

  • Used in resistant hypertension, hypertensive emergencies in pregnancy (eclampsia/preeclampsia).

C. Antineoplastic Hydrazides

• Procarbazine

  • Mechanism: Alkylating-like activity, DNA synthesis inhibition.

  • Used in Hodgkin lymphoma (often in MOPP regimen).

D. Other Pharmacological Agents

• Some hydrazide derivatives have monoamine oxidase inhibitory activity, anti-inflammatory, or antifungal properties.

• Research continues into hydrazide scaffolds for enzyme inhibition in cancer and infectious diseases.

---

4. Mechanisms of Action (Selected)

• Enzyme inhibition: Inhibit critical bacterial enzymes (e.g., InhA in TB).

• Reactive metabolite formation: Activated by host/bacterial enzymes into radicals that disrupt nucleic acids and proteins.

• Vasodilation: Direct smooth muscle relaxation (hydralazine).

• Cytotoxicity: Alkylation and DNA damage (procarbazine).

---

5. Pharmacokinetics (General Patterns)

• Absorption: Many hydrazides are well absorbed orally.

• Distribution: Variable protein binding; hydrophilic compounds distribute mainly in extracellular fluids.

• Metabolism: Often undergo acetylation in the liver (isoniazid – subject to genetic “fast” and “slow” acetylator phenotypes).

• Excretion: Primarily renal, as unchanged drug or metabolites.

---

6. Adverse Effects

Isoniazid

• Hepatotoxicity (dose-related, increased with age/alcohol).

• Peripheral neuropathy (due to pyridoxine deficiency – prevented by supplementation).

• CNS effects: Seizures, psychosis (rare).

Hydralazine

• Reflex tachycardia, headache, fluid retention.

• Drug-induced lupus-like syndrome (especially in slow acetylators).

Procarbazine

• Bone marrow suppression, nausea, neurotoxicity.

• Monoamine oxidase inhibition → dietary tyramine interaction risk.

---

7. Contraindications and Precautions

• Isoniazid: Active liver disease, prior severe isoniazid reaction.

• Hydralazine: Coronary artery disease, rheumatic mitral valve disease.

• Procarbazine: Concomitant MAO inhibitor therapy, recent alcohol use.

---

8. Drug Interactions

• Isoniazid: Inhibits CYP450 enzymes – increases levels of phenytoin, carbamazepine, warfarin.

• Hydralazine: Enhanced hypotension with other antihypertensives.

• Procarbazine: Dangerous hypertensive crisis with tyramine-rich foods; potentiates CNS depressants.

---

9. Clinical Use Considerations

• Resistance testing in TB before isoniazid initiation in resistant regions.

• Genetic acetylator status may influence dosing and toxicity.

• Co-administration of pyridoxine with isoniazid to prevent neuropathy.

• Hydralazine often combined with beta-blocker and diuretic to offset reflex tachycardia and fluid retention.

---

10. Research and Development

• Novel hydrazide derivatives explored for multi-drug resistant TB.

• Hydrazide scaffolds investigated in enzyme-targeted anticancer agents.

• Efforts to improve selectivity, reduce toxicity, and bypass resistance mechanisms.